Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Adequate relief (AR) of irritable bowel syndrome (IBS) symptoms (IBS-AR) has been used as a primary end point in many randomized controlled trials of IBS and is considered by the Rome III committee to be an acceptable primary end point. However, controversy exists on whether baseline severity confounds the effect of the treatment outcome. The aim (1) is to compare a subjective report of IBS-AR with global assessment of improvement (IBS-GAI), change in IBS symptom severity scale (IBS-SSS), and IBS quality of life (IBS-QOL); (2) to explore whether initial IBS symptom severity influences the ability of these outcome measures to detect differences post treatment; and (3) to determine whether psychological symptoms influence the sensitivity of these measures, in a randomized controlled treatment trial. METHODS: A total of 289 adult IBS patients were recruited to a treatment trial. Baseline IBS-SSS scores were used to classify IBS severity as mild (<175), moderate (175-300), or severe (>300). Questionnaires were completed at baseline and after 3 weeks of treatment with sham acupuncture or wait-list control. RESULTS: IBS baseline severity (IBS-SSS) significantly affected the proportion of patients who reported IBS-AR at 3 weeks (mild, 70%; moderate, 49.7%; severe, 38.8%) (P<0.05). However, once the patients who reported IBS-AR at baseline (28.0%) were excluded from the analysis, baseline severity no longer affected the proportion of patients reporting IBS-AR. Baseline severity did not have a significant effect on patients reporting moderate or significant improvement on the IBS-GAI (mild, 30%; moderate, 25.3%; severe, 18.8%) (P=NS). Psychological symptoms had no significant correlations with responders after adjusting for baseline severity. CONCLUSIONS: These data suggest that IBS-AR as an end point is inversely related to baseline symptom severity. However, if patients who report AR at screening were excluded from study participation, baseline symptom severity was no longer confounded with a report of AR at the study end point.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Self-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424
Self-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Whitehead, W. E., Palsson, O. S., Levy, R. L., Feld, A. D., VonKorff, M., & Turner, M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00535.x · Cited by 64
Cited by
Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Nardelli, A., Bolino, C., Lau, J. T., Martin, F.-P., Cominetti, O., Welsh, C., Rieder, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.003 · Cited by 821
Johnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
Self-citationIrritable bowel syndrome symptom severity improves equally with probiotic and placebo
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A. C., & Veijola, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10631 · Cited by 106
Camilleri, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.20 · Cited by 16
Metadata
- Authors
- Passos, M. C. F., Lembo, A. J., Conboy, L. A., Kaptchuk, T. J., Kelly, J. M., Quilty, M. T., Kerr, C. E., Jacobson, E. E., Hu, R., Friedlander, E., & Drossman, D. A.
- Venue
- The American Journal of Gastroenterology
- Published
- 2009-03-17
- Volume
- 104
- Issue
- 4
- Pages
- 912-919
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2051017216
- Cited by
- 60
- References
- 7
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.